Boehringer Ingelheim will reveal on Monday at the European Society for Sexual Medicine conference data from trials of more than 5,000 European and U.S. women for its druig that could improve a woman's desire. Stay tuned for the unveiling of Flibanserin data.

It is sure to be a major media event.

To read more about low desire check out www.TWSHF.org and our various brochures and resources.